The specter of generic challenges has consistently loomed over copyright’s iconic drug, Viagra, triggering questions about the prospects of connected medicinal stakes. While early years saw significant profits, the intellectual property lapse has created the way for less expensive alternatives, likely reducing revenue and posing a genuine hazard